Press

Press release

MAR | Successful rights issue enables increased
focus on strategic initiatives

 

The fourth quarter of 2019 was eventful, and we had the opportunity to see progress
in several areas. Importantly, we closed a rights issue of SEK 43 million, before
transaction costs, securing our ability to execute our plans and activities moving
forward.

PM_Acarix_YearEndReport_2019_eng

Acarix Year-end report 2019

PM_Acarix_YearEndReport_2019_sv

Acarix Bokslutkommunike 2019

 

 

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.